primary outcome (%)

1
Cumulative incidence of primary endpoint with intensive vs. standard lipid-lowering in treatment-resistant hypertension Primary endpoint: death from CHD, non-fatal non- procedure-related MI, resuscitation after cardiac arrest , fatal or non-fatal stroke Primary outcome (%) Atorvastatine 10 mg Atorvastatine 80 mg 30 20 10 0 0 1 2 3 4 5 Bangalore et al., Eur Heart J 2014 Follow-up (years)

Upload: penelope-duncan

Post on 30-Dec-2015

9 views

Category:

Documents


0 download

DESCRIPTION

Atorvastatine 10 mg. Cumulative incidence of primary endpoint with intensive vs. standard lipid-lowering in treatment-resistant hypertension. 30. Atorvastatine 80 mg. - PowerPoint PPT Presentation

TRANSCRIPT

Page 1: Primary outcome (%)

Cumulative incidence of primary endpoint with intensive vs. standard lipid-lowering in treatment-resistant hypertension

Primary endpoint: death from CHD, non-fatal non-procedure-related MI, resuscitation after cardiac arrest , fatal or non-fatal stroke

Prim

ary

outc

ome

(%)

Atorvastatine 10 mgAtorvastatine 80 mg30

20

10

00 1 2 3 4 5

Bangalore et al., Eur Heart J 2014

Follow-up (years)